How to Help Your Patients Save Money on Amoxicillin/Vonoprazan: A Provider's Guide to Savings Programs

Amoxicillin/Vonoprazan (Voquezna Dual Pak) is an important addition to the H. pylori treatment toolkit — but at a retail price of $835–$1,014 per 14-day course, cost is a real barrier for many patients. This guide equips prescribers and care teams with a complete understanding of the savings landscape so that no patient has to forgo effective treatment due to cost.

Understanding the Cost Burden

Voquezna Dual Pak's high cost stems from its brand-only status — no generic vonoprazan is available in the U.S. as of 2026. This places it in a very different category from the alternative H. pylori regimens, most of which use generic components costing $30–$80 total.

From a population health perspective, this cost differential matters. For commercially insured patients with the Savings Card, the drug becomes accessible at $25. For Medicare/Medicaid patients or uninsured patients without manufacturer support, the cost can be a prohibitive barrier.

The Voquezna Savings Card: Program Details for Providers

Phathom Pharmaceuticals offers the Voquezna Savings Card for Voquezna Dual Pak. Key program details for prescribers and care coordinators:

• Patient cost: As little as $25 per fill
• Per-fill cap: $316 (manufacturer covers the difference between patient cost and full copay up to $316 per fill)
• Number of fills: Up to 2 fills
• Eligibility: U.S. resident, 18+, with commercial drug insurance that covers Voquezna Dual Pak
• Not eligible: Medicare, Medicaid, TRICARE, VA, DoD, or other government programs
• Card activation: Required at voquezna.com/hp/savings-card before pharmacy use
• Card expiration: 12/31/2026

Clinical staff can proactively print or email the Savings Card URL to patients at the time of prescribing — don't wait for patients to find it on their own. Since the savings are only available to commercially insured patients, your first task is to quickly identify insurance status during the prescribing visit.

Prior Authorization Strategy to Maximize Coverage

Many commercial and Part D plans place Voquezna Dual Pak at Tier 3 or Tier 4 with prior authorization (PA) requirements. Getting PA approved is essential — without it, the patient pays full retail ($835–$1,014) even with the Savings Card, because the card requires the insurance to cover the drug first.

Effective PA documentation for Voquezna Dual Pak should include:

• Positive H. pylori test documentation (UBT, stool antigen, or endoscopy biopsy results)
• Reference to 2024 ACG guideline support for vonoprazan dual therapy as a first-line empiric alternative
• If the patient has clarithromycin allergy, intolerance, or is in a high-resistance region: document this as clinical rationale for avoiding clarithromycin-based regimens
• If prior PPI-based therapy failed: document the prior treatment failure as clinical rationale for a PCAB-based regimen

Handling Medicare and Medicaid Patients

For Medicare and Medicaid patients, the Savings Card is not available. Options to discuss with the patient:

• Check Part D formulary: Some Medicare Part D plans do cover Voquezna Dual Pak. Use Medicare.gov's Plan Finder to check the patient's specific plan. If it's covered, tier placement and copay still matter — review with the patient.
• Exception request: If the plan doesn't cover it, you can request a formulary exception. Document medical necessity, noting that the 2024 ACG guidelines support vonoprazan dual therapy.
• Switch to a covered alternative: For Medicare/Medicaid patients who cannot access Voquezna Dual Pak affordably, bismuth quadruple therapy using all-generic components ($30–$80 total) is the most cost-effective effective alternative and is covered by virtually all formularies.

When Is Switching to a Cheaper Alternative the Right Call?

For certain patient populations, a lower-cost alternative is clinically equivalent and more accessible:

• Uninsured patients: Bismuth quadruple therapy at $30–$80 is 85–90% effective and universally accessible.
• Medicare patients without coverage: Same recommendation — BQT components are on Tier 1–2 of virtually all Part D plans.
• Patients who have already failed Voquezna Dual Pak: Rifabutin triple therapy (Talicia) is the recommended salvage option if vonoprazan-based therapy fails.

Practice Integration: A Quick Checklist

• At time of prescribing: Confirm insurance type (commercial vs. government program)
• Commercially insured: Provide Savings Card URL (voquezna.com/hp/savings-card), pre-submit PA if required
• Medicare/Medicaid: Check Part D formulary; if unavailable at acceptable cost, offer BQT
• Uninsured: Discuss BQT as the cost-effective alternative upfront; avoid prescribing a $1,000 drug to someone who will be unable to fill it

The Bottom Line for Providers

A proactive, insurance-aware prescribing workflow can make Amoxicillin/Vonoprazan accessible to most commercially insured patients at minimal out-of-pocket cost. For government program patients or uninsured patients, bismuth quadruple therapy remains the accessible, guideline-supported alternative. Integrating the Savings Card into your prescribing workflow — alongside medfinder's pharmacy availability tools at medfinder.com/providers — ensures your patients can actually fill and start their H. pylori treatment without delay.